# US 6,727,063 B1 · Single nucleotide polymorphisms in genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,063 B1
- Document ID: US6727063B1
- Status: Granted
- Kind: B1
- Application number: 09/657,472
- Filed: 2000-09-07
- Granted: 2004-04-27
- Earliest claimed: 1999-09-10
- Assignees: Millennium Pharmaceuticals, Inc.; Whitehead Institute for Biomedical Research
- Inventors: Eric S. Lander; Michele Cargill; James S. Ireland; Stacey Bolk; George Q. Daley; Jeanette J. McCarthy
- Web page: https://patentgrep.com/patent/US6727063B1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from a gene, including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis. A role for the thrombospondin gene(s) in vascular disease is also disclosed. Use of single nucleotide polymorphisms in the thrombospondin gene(s) for diagnosis, prediction of clinical course and treatment response, development of therapeutics and development of cell-culture-based and animal models for research and treatment are disclosed.

## Claims

### Claim 1

A method for predicting the likelihood that a human will have myocardial infraction, comprising:
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene having the nucleotide sequence of SEQ ID NO: 3 in a nucleic acid sample obtained from a human, wherein presence of a C at nucleotide position 1186 is indicative of increased likelihood of a myocardial infraction in the human as compared with a human having a G at nucleotide position 1186, thereby predicting the likelihood that a human will have myocardial infraction.

### Claim 2

A method for predicting the likelihood that a human will have coronary revascularization, comprising:
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene having the nucleotide sequence of SEQ ID NO: 3 from a nucleic acid sample obtained from a human, wherein presence of a C at nucleotide position 1186 is indicative of increased likelihood of a coronary revascularization in the human as compared with a human having a G at nucleotide position 1186, thereby predicting the likelihood that a human will have coronary revascularization.

### Claim 3

A method for predicting the likelihood that a human will have myocardial infraction, comprising:
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene having the nucleotide sequence of SEQ ID NO: 3 in a nucleic acid sample obtained form a human, wherein presence of a G at nucleotide position 1186 is indicative of decreased likelihood of a myocardial infraction in the human as compared with a human having a C at nucleotide position 1186, thereby predicting the likelihood that a human will have myocardial infraction.

### Claim 4

A method for predicting the likelihood that a human will have coronary revascularization, comprising:
determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene having the nucleotide sequence of SEQ ID NO: 3 from a nucleic acid sample obtained from a human, wherein presence of a G at nucleotide position 1186 is indicative of decreased likelihood of a coronary revascularization in the human as compared with a human having a C at nucleotide position 1186, thereby predicting the likelihood that a human will have coronary revascularization.
